Last update Aug. 21, 2022
Very Low Risk
Peginterferon alfa or pegylated interferon alfa-2a is a conjugation of interferon alfa with a 20,000 dalton methoxy-polyethylene glycol (PEG) molecule, with the aim of increasing the half-life of interferon alfa to delay its elimination from the body, in addition to improving certain properties of the drug. It has the same indications as interferon alfa. Subcutaneous administration.
Since the last update we have not found published data on the excretion of peginterferon alfa in breast milk, but excretion of interferon alfa-2b into breast milk is negligible (Haggstrom 1996, Kumar 2000), polyethylene glycol is not excreted in breast milk (Clowse 2017), and no effects were reported in an infant whose mother was given Interferon alfa-2b. (Williams 1994 )
The American Academy of Pediatrics considers interferon Alfa as a medication usually compatible with breastfeeding. (AAP 2001)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM